Cosmo Pharmaceuticals N.V./€COPN
1D1W1MYTD1Y5YMAX
Capital at risk
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.
- Ticker
- €COPN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 365
- Headquarters
- Dublin, Ireland
COPN Metrics
BasicAdvanced
€996M
-
-€0.38
1.48
€2.10
3.62%
Price and volume
Market cap
€996M
Beta
1.48
52-week high
€142.00
52-week low
€55.00
Average daily volume
28K
Dividend rate
€2.10
Financial strength
Current ratio
10.662
Quick ratio
9.836
Long term debt to equity
0.006
Total debt to equity
0.008
Interest coverage (TTM)
-65.87%
Profitability
EBITDA (TTM)
1.204
Gross margin (TTM)
45.51%
Net profit margin (TTM)
-6.19%
Operating margin (TTM)
-10.84%
Effective tax rate (TTM)
-53.39%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-1.07%
Return on equity (TTM)
-1.19%
Valuation
Price to revenue (TTM)
9.323
Price to book
1.66
Price to tangible book (TTM)
4.29
Price to free cash flow (TTM)
-36.83
Free cash flow yield (TTM)
-2.72%
Free cash flow per share (TTM)
-1.575
Dividend yield (TTM)
3.62%
Forward dividend yield
3.62%
Growth
Revenue change (TTM)
-43.66%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
-0.50%
10-year revenue growth (CAGR)
3.57%
3-year earnings per share growth (CAGR)
-16.78%
10-year earnings per share growth (CAGR)
-8.60%
3-year dividend per share growth (CAGR)
25.99%
10-year dividend per share growth (CAGR)
4.14%
Bulls say / Bears say
Recurring revenue rose 18% in H1 2026, led by Winlevi up 38%, Lialda up 35% and CDMO up 14%. Cosmo reaffirmed 2026 revenue guidance of €105–110 million and EBITDA guidance of €10.5–13.5 million. (Cosmo Pharmaceuticals, Investing.com)
Clascoterone 5% topical solution produced positive 12-month Phase III efficacy and safety data, with statistically significant continued hair growth and preparations under way for US and European filings. If approved, the hair-loss treatment could add a sizeable new growth platform beyond Cosmo’s current products. (MarketScreener, Cosmo Pharmaceuticals)
Cosmo ended H1 2026 with €205.1 million in cash, cash equivalents and investments and no financial debt. That balance sheet gives it room to fund its pipeline, expand GI Genius and pursue partnerships without relying on new borrowing. (Cosmo Pharmaceuticals, Investing.com)
H1 2026 revenue was €50.2 million, while EBITDA fell to a small loss and the operating loss widened to €6.6 million. Meeting the full-year EBITDA target therefore depends on a material improvement in the second half. (Investing.com, Bitget)
The hair-loss opportunity remains unapproved: Cosmo is targeting US filing in early 2027 and European filing later in 2027. Regulatory review, further clinical analysis and reliance on partners could delay or reduce the product’s eventual commercial value. (MarketScreener, Stockwatch)
The investment case still relies on a relatively narrow product base and partner execution. Recent commentary also flags pricing pressure and generic competition in legacy gastrointestinal products, which could limit the benefit from Winlevi expansion. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Upcoming events
No upcoming events
Funds containing COPN
AllEURGBP
Fund name | Fund size | €COPN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.04% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.